Literature DB >> 18220561

Quantitative correlations among CYP3A sensitive substrates and inhibitors: literature analysis.

Isabelle Ragueneau-Majlessi1, Xavier Boulenc, Clemence Rauch, Houda Hachad, René H Levy.   

Abstract

As a follow-up to the new classification of CYP3A inhibitors, the present work was undertaken to search for quantitative correlations of AUC ratios between sensitive substrates and midazolam (reference). A large set of clinical studies was obtained utilizing the M&T Drug Interaction Database, and recent Product Labels. Linear relationships were found between midazolam and four CYP3A substrates: simvastatin, buspirone, triazolam and eplerenone. Simvastatin and buspirone were consistently more sensitive than midazolam, independent of the inhibitor. Quantitative correlations of AUC ratios between four CYP3A inhibitors (fluconazole, erythromycin, verapamil, diltiazem) and ketoconazole (400 mg/day) were also uncovered. The average potencies of these inhibitors relative to ketoconazole were 27% for erythromycin, 17% for fluconazole and 19% for verapamil.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18220561     DOI: 10.2174/138920007782798135

Source DB:  PubMed          Journal:  Curr Drug Metab        ISSN: 1389-2002            Impact factor:   3.731


  8 in total

1.  Pomegranate juice does not affect the disposition of simvastatin in healthy subjects.

Authors:  Soo-Jin Park; Chang-Woo Yeo; Eon-Jeong Shim; Hyunmi Kim; Kwang-Hyeon Liu; Jae-Gook Shin; Ji-Hong Shon
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2015-02-27       Impact factor: 2.441

2.  Perpetrators of pharmacokinetic drug-drug interactions arising from altered cytochrome P450 activity: a criteria-based assessment.

Authors:  Thomas M Polasek; Frank P Y Lin; John O Miners; Matthew P Doogue
Journal:  Br J Clin Pharmacol       Date:  2011-05       Impact factor: 4.335

3.  Sensitivity of intravenous and oral alfentanil and pupillary miosis as minimal and noninvasive probes for hepatic and first-pass CYP3A induction.

Authors:  E D Kharasch; A Francis; A London; K Frey; T Kim; J Blood
Journal:  Clin Pharmacol Ther       Date:  2011-05-11       Impact factor: 6.875

4.  Reliability and extension of quantitative prediction of CYP3A4-mediated drug interactions based on clinical data.

Authors:  Constance Loue; Michel Tod
Journal:  AAPS J       Date:  2014-10-02       Impact factor: 4.009

5.  Investigation of combined CYP3A4 inductive/inhibitory properties by studying statin interactions: a model study with the renin inhibitor ACT-178882.

Authors:  Jasper Dingemanse; Laurent B Nicolas; Luc van Bortel
Journal:  Eur J Clin Pharmacol       Date:  2014-04-15       Impact factor: 2.953

Review 6.  Should All Patients with Resistant Hypertension Receive Spironolactone?

Authors:  Ján Rosa; Tomáš Zelinka; Ondřej Petrák; Branislav Štrauch; Robert Holaj; Jiří Widimský
Journal:  Curr Hypertens Rep       Date:  2016-11       Impact factor: 5.369

7.  Effects of Cytochrome P450 3A4 Inhibitors-Ketoconazole and Erythromycin-on Bitopertin Pharmacokinetics and Comparison with Physiologically Based Modelling Predictions.

Authors:  Christophe Boetsch; Neil Parrott; Stephen Fowler; Agnes Poirier; Dominik Hainzl; Ludger Banken; Meret Martin-Facklam; Carsten Hofmann
Journal:  Clin Pharmacokinet       Date:  2016-02       Impact factor: 6.447

8.  A useful tool for drug interaction evaluation: the University of Washington Metabolism and Transport Drug Interaction Database.

Authors:  Houda Hachad; Isabelle Ragueneau-Majlessi; René H Levy
Journal:  Hum Genomics       Date:  2010-10       Impact factor: 4.639

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.